13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
78 檔
31.4%
According to the latest 13F quarterly dataset, Blue Owl Capital Holdings LP managed an equity portfolio of $664.5M at the end of Q4 2024, spanning 78 distinct U.S. exchange-listed positions.
In Q4 2024, Blue Owl Capital Holdings LP adopted a defensive or profit-taking posture, trimming 12 positions and completely liquidating 16 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NCDL | Nuveen Churchill Direct Lend | Stock-Other | 15.99% | -3.32% | — | |
| 2 | KVYO | Klaviyo Inc-a | Stock-Other | 10.49% | — | -9.97% | |
| 3 | PLRX | Pliant Therapeutics Inc | Stock-Other | 8.60% | -1.01% | EXIT | |
| 4 | OBDC | Blue Owl Capital CORP | Stock-Financials | 7.29% | -2.73% | — | |
| 5 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 6.81% | -3.07% | +17.90% | |
| 6 | CNDT | Conduent Inc | Stock-Other | 5.36% | -0.62% | +67.27% | |
| 7 | TRML | Tourmaline Bio Inc | Stock-Other | 5.16% | — | -29.47% | |
| 8 | ✓ | Engene Holdings Inc | Stock-Other | 4.96% | -8.08% | EXIT | |
| 9 | EVCM | Evercommerce Inc | Stock-Other | 4.26% | — | — | |
| 10 | LRMR | Larimar Therapeutics Inc | Stock-Other | 4.25% | -4.40% | +11.67% | |
| 11 | HLLY | Holley Inc | Stock-Other | 2.13% | -1.81% | +17.56% | |
| 12 | ✓ | Acelyrin Inc | Stock-Other | 2.06% | — | -0.36% | |
| 13 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.90% | -0.84% | — | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 1.80% | — | -31.38% | |
| 15 | ✓ | Ikena Oncology Inc | Stock-Other | 1.58% | — | — | |
| 16 | CNTX | Context Therapeutics Inc | Stock-Other | 1.57% | -3.34% | +17.49% | |
| 17 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 1.41% | +1.00% | -20.91% | |
| 18 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.26% | — | — | |
| 19 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.17% | -0.78% | -27.57% | |
| 20 | EYPT | Eyepoint Inc | Stock-Other | 1.17% | -1.52% | — | |
| 21 | RPTX | Repare Therapeutics Inc | Stock-Other | 1.06% | — | +2.11% | |
| 22 | ETWOGBP | E2open Parent Holdings Inc | Stock-Other | 1.04% | — | — | |
| 23 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.01% | -2.99% | +2.60% | |
| 24 | KROS | Keros Therapeutics Inc | Stock-Other | 0.91% | — | +97.85% | |
| 25 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.87% | — | -13.73% | |
| 26 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.76% | -0.91% | -26.53% | |
| 27 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.71% | -0.22% | — | |
| 28 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.71% | — | -3.57% | |
| 29 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.56% | — | -20.64% | |
| 30 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.41% | -0.07% | — | |
| 31 | ✓ | Stock-Other | 0.39% | — | -8.73% | ||
| 32 | ✓ | Adc Therapeutics SA | Stock-Other | 0.34% | -0.58% | — | |
| 33 | GOCOQ | Gohealth Inc-class A | Stock-Other | 0.26% | -0.02% | EXIT | |
| 34 | EPD | Enterprise Products Partners | Stock-Energy | 0.23% | -0.32% | EXIT | |
| 35 | OHI | Omega Healthcare Investors, Inc. | Stock-Real Estate | 0.19% | — | — | |
| 36 | ✓ | Stock-Other | 0.16% | — | — | ||
| 37 | ✓ | Stock-Other | 0.16% | — | — | ||
| 38 | ✓ | Marblegate Acquisition Corp | Stock-Other | 0.15% | — | — | |
| 39 | CMPS | Compass Pathways PLC | Stock-Other | 0.14% | +0.96% | NEW | |
| 40 | GTLB | Gitlab Inc-cl A | Stock-Tech | 0.13% | — | — | |
| 41 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.11% | — | — | |
| 42 | ✓ | Rezolve Ai LTD | Stock-Other | 0.11% | -0.02% | — | |
| 43 | ✓ | Alpha Partners Technology Merg | Stock-Other | 0.05% | — | — | |
| 44 | SLND-WS | Legato Merger CORP Ii -cw23 | Stock-Other | 0.05% | -0.01% | — | |
| 45 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.05% | -0.10% | EXIT | |
| 46 | OPTX | Syntec Optics Holdings Inc | Stock-Other | 0.03% | — | — | |
| 47 | AMODW | Insight Acquisition Co -cw23 | Stock-Other | 0.02% | -0.01% | — | |
| 48 | PLMKW | Plum Acquisition Corp. IV | Stock-Other | 0.02% | — | — | |
| 49 | OPTXW | Omnilit Acquisition Cl A -23 | Stock-Other | 0.02% | -0.23% | EXIT | |
| 50 | ✓ | Satixfy Communications LTD | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CNDT | Conduent Inc | +2.6% | +67.27% | Add |
| 2 | GOCOQ | Gohealth Inc-class A | +2.4% | — | Unchanged |
| 3 | KVYO | Klaviyo Inc-a | +2.1% | -9.97% | Trim |
| 4 | NCDL | Nuveen Churchill Direct Lend | +2.1% | — | Unchanged |
| 5 | PLRX | Pliant Therapeutics Inc | +1.9% | -7.82% | Trim |
| 6 | ELDN | Eledon Pharmaceuticals Inc | +1.9% | NEW | New buy |
| 7 | OBDC | Blue Owl Capital CORP | +1.4% | — | Unchanged |
| 8 | TNGX | Tango Therapeutics Inc | +1.2% | NEW | New buy |
| 9 | EYPT | Eyepoint Inc | +1.2% | NEW | New buy |
| 10 | ✓ | Engene Holdings Inc | +1% | +3.30% | Add |
| 11 | EVCM | Evercommerce Inc | +0.9% | — | Unchanged |
| 12 | PVLA | Palvella Therapeutics Inc | +0.7% | NEW | New buy |
| 13 | HLLY | Holley Inc | +0.6% | +17.56% | Add |
| 14 | SGMT | Sagimet Biosciences Inc-a | +0.5% | -20.91% | Trim |
| 15 | MRKR | Marker Therapeutics Inc | +0.4% | NEW | New buy |
| 16 | CGEM | Cullinan Therapeutics Inc | +0.2% | +17.90% | Add |
| 17 | ✓ | +0.2% | NEW | New buy | |
| 18 | CMPS | Compass Pathways PLC | +0.1% | NEW | New buy |
| 19 | IRON | Disc Medicine Inc | +0.1% | -31.38% | Trim |
| 20 | CMPX | Compass Therapeutics Inc | 0% | +2.60% | Add |
| 21 | ✓ | Adc Therapeutics SA | -0.1% | — | Unchanged |
| 22 | MREO | Mereo Biopharma Group Pl-adr | -0.1% | -20.64% | Trim |
| 23 | ✓ | Engene Holdings Inc | -0.1% | -92.94% | Trim |
| 24 | TQQQ | ProShares UltraPro QQQ | -0.1% | EXIT | Sold out |
| 25 | SYRS | Syros Pharmaceuticals Inc | -0.2% | EXIT | Sold out |
| 26 | NU | Nu Holdings Ltd. | -0.2% | EXIT | Sold out |
| 27 | BLND | Blend Labs Inc-a | -0.3% | EXIT | Sold out |
| 28 | PAYO | Payoneer Global Inc | -0.3% | EXIT | Sold out |
| 29 | ✓ | -0.3% | -8.73% | Trim | |
| 30 | ETWOGBP | E2open Parent Holdings Inc | -0.4% | — | Unchanged |
| 31 | AQST | Aquestive Therapeutics Inc | -0.4% | -26.53% | Trim |
| 32 | ✓ | Inozyme Pharma Inc | -0.4% | -3.57% | Trim |
| 33 | IMVT | Immunovant Inc | -0.4% | EXIT | Sold out |
| 34 | MLYS | Mineralys Therapeutics Inc | -0.5% | EXIT | Sold out |
| 35 | KROS | Keros Therapeutics Inc | -0.5% | +97.85% | Add |
| 36 | BRZE | Braze Inc-a | -0.5% | EXIT | Sold out |
| 37 | VKTX | Viking Therapeutics Inc | -0.5% | EXIT | Sold out |
| 38 | CNTX | Context Therapeutics Inc | -0.5% | +17.49% | Add |
| 39 | GPCR | Structure Therapeutics Inc | -0.6% | EXIT | Sold out |
| 40 | RARE | Ultragenyx Pharmaceutical In | -0.6% | -27.57% | Trim |
| 41 | ✓ | Acelyrin Inc | -0.7% | -0.36% | Trim |
| 42 | JANX | Janux Therapeutics Inc | -0.7% | EXIT | Sold out |
| 43 | PYXS | Pyxis Oncology Inc | -0.8% | EXIT | Sold out |
| 44 | STWD | Starwood Property Trust Inc | -0.9% | EXIT | Sold out |
| 45 | CCC | Ccc Intelligent Solutions Ho | -1% | EXIT | Sold out |
| 46 | ✓ | Lanzatech Global Inc | -1.1% | EXIT | Sold out |
| 47 | LRMR | Larimar Therapeutics Inc | -1.1% | +11.67% | Add |
| 48 | RPTX | Repare Therapeutics Inc | -1.2% | +2.11% | Add |
| 49 | TRML | Tourmaline Bio Inc | -2.6% | -29.47% | Trim |
| 50 | TQQQ | Proshares Ultrapro Qqq | -4.5% | EXIT | Sold out |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 78 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NCDL, KVYO, PLRX) accounted for 31.4% of total reported equity market value during Q4 2024.
Top New Position Initiated
ELDN
市值: $8.1M
Top Position Liquidated / Trimmed
TQQQ
前期市值: $23.6M
During Q4 2024, Blue Owl Capital Holdings LP's top holdings by market value included NCDL (16.0%)、KVYO (10.5%)、PLRX (8.6%). The largest single position, NCDL, represented 16.0% of total portfolio value.
In Q4 2024, Blue Owl Capital Holdings LP made 44 total portfolio adjustments, initiating 7 new buys, adding to 9 positions, trimming 12 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.